2P4.F BIOPORTO A/S B DK 1
- Market cap
- EUR 57.4M
- P/E
- -
- P/B
- 5.34x
- ROE
- 174.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 2P4.F undervalued?
Graham numberThe Graham number of BIOPORTO A/S B DK 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOPORTO A/S B DK 1 fundamental analysis
No fundamental analysis for BIOPORTO A/S B DK 1 yet.
BIOPORTO A/S B DK 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOPORTO A/S B DK 1
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma,…
Full company profileBIOPORTO A/S B DK 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOPORTO A/S B DK 1 annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 24.3M | 29.0M | 31.0M | 36.2M | 40.3M | 27.6M |
| Gross Profit | 15.0M | 19.0M | 20.2M | 24.5M | 30.4M | 17.2M |
| Operating Income | -65.3M | -78.9M | -60.2M | -75.5M | -86.1M | 139M |
| EBITDA | - | -76.5M | -58.0M | -70.9M | -84.6M | 142M |
| Net Income | -57.1M | -75.9M | -56.3M | -68.2M | -82.1M | 144M |
| EPS | -0.21 | -0.22 | -0.15 | -0.16 | -0.17 | 0.29 |
| Balance Sheet | ||||||
| Total Assets | 81.3M | 109M | 89.8M | 96.0M | 93.2M | 109M |
| Total Liabilities | 35.3M | 38.4M | 29.7M | 28.2M | 30.2M | 26.8M |
| Shareholders' Equity | 46.0M | 70.2M | 60.2M | 67.8M | 63.0M | 82.4M |
| Cash & Short-term Investments | 45.5M | 81.8M | 66.4M | 59.7M | 54.9M | 74.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -64.6M | -52.5M | -55.5M | -83.6M | -77.1M | - |
| Capital Expenditure | 389K | 471K | 39.0K | 350K | 0.00 | 0.00 |
| Free Cash Flow | -65.0M | -53.0M | -55.5M | -83.9M | -77.1M | - |
| Ratios | ||||||
| ROE | -124.3% | -108.1% | -93.6% | -100.7% | -130.3% | 174.4% |
| ROA | -70.3% | -69.9% | -62.7% | -71.1% | -88.1% | 131.5% |
| Net Profit Margin | -235.5% | -262.1% | -181.9% | -188.3% | -203.8% | 520.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOPORTO A/S B DK 1 dividends
BIOPORTO A/S B DK 1 has not paid dividends in the last 5 fiscal years.
Who owns BIOPORTO A/S B DK 1
- Insiders 29.80%
- Institutions 6.47%
- Public & others 63.73%
- Shares outstanding 495M
- Free float 459M
BIOPORTO A/S B DK 1 company profile
- Company name
- BIOPORTO A/S B DK 1
- Ticker
- 2P4.F
- ISIN
- DK0011048619
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- Tuborg Havnevej 15, st., Hellerup, Denmark, 2900
- Phone
- 45 45 29 00 00
- Website
- bioporto.com
About BIOPORTO A/S B DK 1
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
BIOPORTO A/S B DK 1 management
7- Mr. Carsten BuhlGroup Chief Executive Officer · born 1973
- Ms. Gry Husby LarsenExecutive VP & Group Chief Legal Officer · born 1980
- Mr. Klaus Juhl WulffCFO & Executive VP · born 1973
- Dr. Jakob FeldingChief Science Officer
- Ms. Hanne SogaardHead of Investor Relations
- Ms. Jennifer ZondermanSenior Vice President of Global Marketing & Commercialization
- Mr. Jeffrey N. HaasPresident & CEO of BioPorto Inc.